annual cash & cash equivalents:
$97.25M-$89.48M(-47.92%)Summary
- As of today (September 16, 2025), PTGX annual cash & cash equivalents is $97.25 million, with the most recent change of -$89.48 million (-47.92%) on December 31, 2024.
- During the last 3 years, PTGX annual cash & cash equivalents has fallen by -$26.42 million (-21.36%).
- PTGX annual cash & cash equivalents is now -47.92% below its all-time high of $186.73 million, reached on December 31, 2023.
Performance
PTGX Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$570.47M-$3.90M(-0.68%)Summary
- As of today (September 16, 2025), PTGX quarterly cash & cash equivalents is $570.47 million, with the most recent change of -$3.90 million (-0.68%) on June 30, 2025.
- Over the past year, PTGX quarterly cash & cash equivalents has increased by +$6.47 million (+1.15%).
- PTGX quarterly cash & cash equivalents is now -0.68% below its all-time high of $574.36 million, reached on March 31, 2025.
Performance
PTGX quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PTGX Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -47.9% | +1.1% |
| 3 y3 years | -21.4% | +95.4% |
| 5 y5 years | +194.6% | +173.4% |
PTGX Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -47.9% | at low | -0.7% | +147.2% |
| 5 y | 5-year | -47.9% | +194.6% | -0.7% | +194.1% |
| alltime | all time | -47.9% | +2298.3% | -0.7% | >+9999.0% |
PTGX Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $570.47M(-0.7%) |
| Mar 2025 | - | $574.36M(+37.1%) |
| Dec 2024 | $97.25M(-47.9%) | $418.91M(-10.6%) |
| Sep 2024 | - | $468.72M(-16.9%) |
| Jun 2024 | - | $564.00M(+74.8%) |
| Mar 2024 | - | $322.63M(-5.6%) |
| Dec 2023 | $186.73M(+48.5%) | $341.62M(+6.5%) |
| Sep 2023 | - | $320.75M(+2.3%) |
| Jun 2023 | - | $313.40M(+35.8%) |
| Mar 2023 | - | $230.76M(-2.8%) |
| Dec 2022 | $125.74M(+1.7%) | $237.35M(-11.2%) |
| Sep 2022 | - | $267.44M(-8.4%) |
| Jun 2022 | - | $291.89M(-4.4%) |
| Mar 2022 | - | $305.29M(-6.6%) |
| Dec 2021 | $123.67M(+5.4%) | $326.90M(+4.0%) |
| Sep 2021 | - | $314.30M(-11.3%) |
| Jun 2021 | - | $354.28M(+29.5%) |
| Mar 2021 | - | $273.48M(-10.6%) |
| Dec 2020 | $117.36M | $305.82M(+57.7%) |
| Sep 2020 | - | $193.98M(-7.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2020 | - | $208.68M(+77.6%) |
| Mar 2020 | - | $117.52M(-11.7%) |
| Dec 2019 | $33.01M(-59.9%) | $133.03M(-3.4%) |
| Sep 2019 | - | $137.70M(+9.2%) |
| Jun 2019 | - | $126.11M(+12.0%) |
| Mar 2019 | - | $112.56M(-12.7%) |
| Dec 2018 | $82.23M(-22.4%) | $128.86M(-7.0%) |
| Sep 2018 | - | $138.53M(+10.7%) |
| Jun 2018 | - | $125.18M(-7.3%) |
| Mar 2018 | - | $134.97M(-6.3%) |
| Dec 2017 | $106.03M(+402.9%) | $144.01M(+53.9%) |
| Sep 2017 | - | $93.60M(+45.1%) |
| Jun 2017 | - | $64.50M(+2.0%) |
| Mar 2017 | - | $63.26M(-18.5%) |
| Dec 2016 | $21.08M(+420.0%) | $77.61M(-21.2%) |
| Sep 2016 | - | $98.53M(+388.1%) |
| Jun 2016 | - | $20.19M(-30.5%) |
| Mar 2016 | - | $29.03M(+616.0%) |
| Dec 2015 | $4.05M(-56.5%) | $4.05M |
| Dec 2014 | $9.32M | - |
FAQ
- What is Protagonist Therapeutics, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Protagonist Therapeutics, Inc.?
- What is Protagonist Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
- What is Protagonist Therapeutics, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Protagonist Therapeutics, Inc.?
- What is Protagonist Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
What is Protagonist Therapeutics, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of PTGX is $97.25M
What is the all time high annual cash & cash equivalents for Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. all-time high annual cash & cash equivalents is $186.73M
What is Protagonist Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, PTGX annual cash & cash equivalents has changed by -$89.48M (-47.92%)
What is Protagonist Therapeutics, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of PTGX is $570.47M
What is the all time high quarterly cash & cash equivalents for Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. all-time high quarterly cash & cash equivalents is $574.36M
What is Protagonist Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, PTGX quarterly cash & cash equivalents has changed by +$6.47M (+1.15%)